共 173 条
[1]
Lip GY(2010)Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 263-272
[2]
Nieuwlaat R(2016)The epidemiology of atrial fibrillation and stroke Cardiol Clin 34 255-268
[3]
Pisters R(2016)2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO) Eur Heart J 74 1359-e88
[4]
Lane DA(2016)2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS Eur J Cardiothorac Surg 50 e1-1955
[5]
Crijns HJ(2016)Treatment of venous thromboembolism with new anticoagulant agents J Am Coll Cardiol 67 1941-204
[6]
Pistoia F(2018)Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: systematic review and meta-analysis PLoS ONE 13 202-30
[7]
Sacco S(2010)Subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients J Thromb Haemost 8 24-172
[8]
Tiseo C(2021)5-year outcomes from rivaroxaban therapy in atrial fibrillation: results from the Dresden NOAC Registry Thromb Res 2021 164-784
[9]
Degan D(2022)Bleeding and thromboembolic events in patients with non-valvular atrial fibrillation treated with apixaban or rivaroxaban Malays J Med Sci 29 777-204
[10]
Ornello R(2015)The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations Ann Intern Med 162 202-1636